Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.

Author: Shumin CHEN ¹ ; Ye LI ¹ ; Zheng WANG ¹ ; Lin FENG ¹ ; Yueping JIA ² ; Xiaodong MO ¹ ; Yu WANG ¹ ; Qian JIANG ¹ ; Xiaojun HUANG ¹ ; Yueyun LAI ¹
Author Information

1. Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Publication Type:Letter
MeSH: Humans; Receptors, Chimeric Antigen/therapeutic use*; DNA-Binding Proteins/genetics*; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2/genetics*; Cell- and Tissue-Based Therapy; Oncogene Proteins, Fusion/genetics*; Translocation, Genetic
From: Chinese Medical Journal 2023;136(11):1382-1384
CountryChina
Language:English